Diana P. English, MD, a gynecologic oncologist at Stanford Hospital and Clinics, discusses an investigational antibody-drug conjugate (ADC) in ovarian cancer.
Diana P. English, MD
Advertisement
Articles by Diana P. English, MD
Diana P. English, MD, a gynecologic oncologist at Stanford Hospital and Clinics, discusses the development of the antibody drug conjugate (ADC) mirvetuximab soravtansine in ovarian cancer.
Advertisement
Latest Updated Articles
Dr. English on Mirvetuximab Soravtansine in Ovarian CancerDecember 19th 2018
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
3
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
4
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
5